Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Qilu Announces $235 Million Deal for Cend's Immunotherapy

publication date: Feb 17, 2021

Qilu Pharma of Jinan formed a $235 million collaboration with San Diego's Cend Therapeutics to develop and commercialize Cend’s immunotherapy in China. CEND-1 is an investigational drug that modifies the tumor microenvironment. It has a dual mechanism, activating a novel uptake pathway to allow therapeutic drugs into the tumor while it also depletes immunosuppressive cells. CEND-1 is in a Phase II trial to treat pancreatic cancer. Qilu will pay $10 million upfront and up to $225 million in milestones, plus royalties. More details....


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital